The status quo of targeted therapy in bladder cancer / 医学研究生学报
Journal of Medical Postgraduates
;
(12): 552-556, 2019.
Artigo
em Chinês
| WPRIM
| ID: wpr-818278
ABSTRACT
Bladder cancer is the most common malignant tumor of the urinary system. Prognosis of advanced or metastatic bladder urothelial carcinoma is usually poor. More than half of the patients cannot receive standard, first-line cisplatin-based chemotherapy due to renal dysfunction, cachexia or other complications. As targeted drugs shine in cancer treatment, targeted therapy for bladder cancer has also entered clinical research. This article reviews the targeted therapies include human epithelial growth factor family, vascular endothelial growth factor and receptor, fibroblast growth factor receptor, phosphoinositide 3-kinase-AKT-mammalian target of rapamycin.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Tipo de estudo:
Estudo prognóstico
Idioma:
Chinês
Revista:
Journal of Medical Postgraduates
Ano de publicação:
2019
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS